SCHEMBL3277113

SCHEMBL3277113

CCCCCCc1[c]cc(CCCCCC)[c]c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.40
ESR1 P03372 2/20 0.40
ADRA2A P08913 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
TACR2 P21452 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
KCNH2 Q12809 2/20 0.40
CYP3A4 P08684 2/20 0.40
ACHE P22303 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
SHBG P04278 1/20 0.40
TP53 P04637 1/20 0.40
HSPD1 P10809 1/20 0.40
ADRB3 P13945 1/20 0.40
HTR2C P28335 1/20 0.40
HSPE1 P61604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243639 1.00 PTGS2 (0.40) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL4624237 1.00 PTGS2 (0.40) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL2883267 1.00 PTGS2 (0.40) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL4623440 1.00 PTGS2 (0.40) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL8390626 0.89 PTGS2 (0.34) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL3423379 0.81 PTGS2 (0.34) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL1717330 0.81 PTGS2 (0.34) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL1717457 0.81 PTGS2 (0.34) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL7570539 0.81 PTGS2 (0.34) PTGS2ESR1ADRA2AADORA3TACR2
SCHEMBL11787936 0.81 PTGS2 (0.34) PTGS2ESR1ADRA2AADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2766046-B1 METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES UNIV CALIFORNIA (US) 2017-08-02 EP disclosed
US-9669098-B2 Metal-organic frameworks with exceptionally large pore aperatures THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-06-06 US disclosed
US-20160008472-A1 METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES UNITED STATES DEPARTMENT OF ENERGY 2016-01-14 US disclosed
US-9078922-B2 Metal-organic frameworks with exceptionally large pore aperatures THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-07-14 US disclosed
US-20130096210-A1 METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-04-18 US disclosed
US-8207337-B2 Reagent for organic synthesis reaction containing organic triol borate salt WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-06-26 US disclosed
US-20100087646-A1 REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-08 US disclosed
EP-1337520-B1 SUBSTITUTED 5-ARYL AND 5-HETEROARYL-2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE DERIVATIVES AS UV ABSORBERS CIBA SC HOLDING AG (CH) 2004-12-15 EP disclosed
EP-1337520-A1 SUBSTITUTED 5-ARYL AND 5-HETEROARYL-2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE DERIVATIVES AS UV ABSORBERS Ciba SC Holding AG (CH) 2003-08-27 EP disclosed
WO-2002042281-A1 SUBSTITUTED 5-ARYL AND 5-HETEROARYL-2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE DERIVATIVES AS UV ABSORBERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-05-30 WO disclosed
EP-0579604-A1 CONDUCTIVE POLYMERS WITH CONJUGATED DOUBLE BONDS. WAKKER CHEMIE GMBH (DE) 1994-01-26 EP disclosed
WO-1992018552-A1 CONDUCTIVE POLYMERS WITH CONJUGATED DOUBLE BONDS WACKER-CHEMIE GMBH (DE) 1992-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087646-A1 REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT ORC3, OXSR1, OSTC PTGS2 4673/4885ESR1 1651/4885ADRA2A 4327/4885
US-20160008472-A1 METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES AP3M1, AP2M1, AP2A2 PTGS2 2129/4885ESR1 3788/4885ADRA2A 4332/4885
US-20130096210-A1 METAL-ORGANIC FRAMEWORKS WITH EXCEPTIONALLY LARGE PORE APERATURES AP3M1, AP2M1, AP2A2 PTGS2 2129/4885ESR1 3788/4885ADRA2A 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.